S
Steven E. Nissen
Researcher at Cleveland Clinic
Publications - 615
Citations - 68676
Steven E. Nissen is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Intravascular ultrasound & Coronary artery disease. The author has an hindex of 98, co-authored 569 publications receiving 61223 citations. Previous affiliations of Steven E. Nissen include Cairo University & Cleveland Clinic Lerner College of Medicine.
Papers
More filters
Journal ArticleDOI
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Steven E. Nissen,Kathy Wolski +1 more
TL;DR: Patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes mellitus as well as the availability of outcome data for myocardial infarction and death from cardiovascular causes.
Journal ArticleDOI
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso,Gilbert H. Daniels,Kirstine Brown-Frandsen,Peter Lommer Kristensen,Johannes F.E. Mann,Michael A. Nauck,Steven E. Nissen,Stuart J. Pocock,Neil R Poulter,Lasse Steen Ravn,William M. Steinberg,Mette Stockner,Bernard Zinman,Richard M. Bergenstal,John B. Buse +14 more
TL;DR: In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, orNonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo.
Journal ArticleDOI
Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis A Randomized Controlled Trial
Steven E. Nissen,E. Murat Tuzcu,Paul Schoenhagen,B. Greg Brown,Peter Ganz,Robert A. Vogel,Tim Crowe,Christopher J. Cooper,Bruce R. Brodie,Cindy L. Grines,Anthony N. DeMaria +10 more
TL;DR: For patients with coronary heart disease, intensive lipid-lowering treatment with atorvastatin reduced progression of coronary atherosclerosis compared with pravastatin.
Journal ArticleDOI
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White,Christopher P. Cannon,Simon Heller,Steven E. Nissen,Richard M. Bergenstal,George L. Bakris,Alfonso Perez,Penny R. Fleck,Cyrus R. Mehta,Stuart Kupfer,Craig A. Wilson,William C. Cushman,Faiez Zannad +12 more
TL;DR: Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo.
Journal ArticleDOI
American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
Gary S. Mintz,Steven E. Nissen,William D. Anderson,Steven R. Bailey,Raimund Erbel,Peter J. Fitzgerald,Fausto J. Pinto,Kenneth Rosenfield,Robert J. Siegel,E. Murat Tuzcu,Paul G. Yock,Robert A. O'Rourke,Jonathan Abrams,Eric R. Bates,Bruce R. Brodie,Pamela S. Douglas,Gabriel Gregoratos,Mark A. Hlatky,Judith S. Hochman,Sanjiv Kaul,Cynthia M. Tracy,David D. Waters,William L. Winters +22 more
TL;DR: In this article, the authors present an Expert Consensus Document that includes evidence about the standards for the acquisition, measurement, and reporting of intravascular ultrasound studies (IVUS).